A Prospective, Single-center, Randomized, Controlled Study of Sevelamer Carbonate in the Lipid Metabolism and Uric Acid Treatment of Obesity-Related Glomerulopathy

Summary

To observe the decreased levels of low-density lipoprotein from baseline in patients with obesity-related glomerulopathy (ORG) after 12 weeks of Sevelamer Carbonate treatment.

Timeline

Start

2016-01

Primary completion

2018-02

Completion

2018-02

Outcome

Outcome not reported

Stopped (Enrollment): “difficulty in enrollment”

Drugs

Indications